HuGE Literature Finder
Records
1
-
10
Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Jun OF1-OF10. Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC cancer 2019 Jun 19 (1): 595. Fang Wenfeng, Huang Yihua, Hong Shaodong, Zhang Zhonghan, Wang Minghui, Gan Jiadi, Wang Wenjing, Guo Honglin, Wang Kai, Zhang |
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. Cancer research and treatment : official journal of Korean Cancer Association 2017 Jan . Lee Youngjoo, Lee Ki Hyeong, Lee Geon Kook, Lee Soo-Hyun, Lim Kun Young, Joo Jungnam, Go Yun Jung, Lee Jin Soo, Han Ji-Yo |
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung cancer (Amsterdam, Netherlands) 2017 04 106 76-82. Kim Dong-Wan, Garon Edward B, Jatoi Aminah, Keefe Dorothy M, Lacouture Mario E, Sonis Stephen, Gernhardt Diana, Wang Tao, Giri Nagdeep, Doherty Jim P, Nadanaciva Sashi, O'Connell Joseph, Sbar Eric, Cho Byoung Ch |
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors. Cancer research and treatment : official journal of Korean Cancer Association 2016 May . Han Ji-Youn, Lee Ki Hyeong, Kim Sang-We, Min Young Joo, Cho Eunkyung, Lee Youngjoo, Lee Soo-Hyun, Kim Hyae Young, Lee Geon Kook, Nam Byung Ho, Han Hyesun, Jung Jina, Lee Jin S |
Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. Targeted oncology 2015 Jun . Guetz Gaetan Des, Landre Thierry, Uzzan Bernard, Chouahnia Kader, Nicolas Patrick, Morere Jean-Franço |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet. Oncology 2015 Feb 16 (2): 141-51. Yang James Chih-Hsin, Wu Yi-Long, Schuler Martin, Sebastian Martin, Popat Sanjay, Yamamoto Nobuyuki, Zhou Caicun, Hu Cheng-Ping, O'Byrne Kenneth, Feng Jifeng, Lu Shun, Huang Yunchao, Geater Sarayut L, Lee Kye Young, Tsai Chun-Ming, Gorbunova Vera, Hirsh Vera, Bennouna Jaafar, Orlov Sergey, Mok Tony, Boyer Michael, Su Wu-Chou, Lee Ki Hyeong, Kato Terufumi, Massey Dan, Shahidi Mehdi, Zazulina Victoria, Sequist Lecia |
Cetuximab as salvage monotherapy in chemotherapy-refractory metastatic colorectal cancer: A single-center report. Oncology letters 2013 Oct 6 (4): 1011-1014. Mekata Eiji, Endo Yoshihiro, Sonoda Hiromichi, Shimizu Tomoharu, Kawai Yuki, Umeda Tomoko, Shiomi Hisanori, Naka Shigeyuki, Kubota Yoshihiro, Murata Satoshi, Yamamoto Hiroshi, Abe Hajime, Tani Toh |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Sep 31 (27): 3327-34. Sequist Lecia V, Yang James Chih-Hsin, Yamamoto Nobuyuki, O'Byrne Kenneth, Hirsh Vera, Mok Tony, Geater Sarayut Lucien, Orlov Sergey, Tsai Chun-Ming, Boyer Michael, Su Wu-Chou, Bennouna Jaafar, Kato Terufumi, Gorbunova Vera, Lee Ki Hyeong, Shah Riyaz, Massey Dan, Zazulina Victoria, Shahidi Mehdi, Schuler Mart |
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2012 May 15 (5): 299-304. Li Jianjie, Qu Lili, Wei Xing, Gao Hongjun, Wang Weixia, Qin Haifeng, Tang Chuanhao, Guo Wanfeng, Wang Hong, Liu Xiaoqi |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 09, 2022
- Content source: